Type 2 Diabetes Mellitus: Update Bulletin [December 2016]

Gain new KOL insights on the latest events happening in type 2 diabetes mellitus (T2DM): positive results from AstraZeneca’s Phase III DURATION-8 study which assessed Bydureon (exenatide extended-release), a glucagon-like peptide-1 (GLP-1) receptor agonist, in combination with Forxiga (dapagliflozin) the sodium glucose co-transporter-2 (SGLT2) inhibitor; a recommendation for approval of Boehringer Ingelheim’s and Eli Lilly’s Glyxambi (empagliflozin/linagliptin) by the European Medicines Agency CHMP; and positive data from Merck & Co.’s and Pfizer’s Phase III VERTIS SITA2 study for ertugliflozin in combination with sitagliptin and metformin.

Business Questions:

• What do KOLs think about the data from the Phase III DURATION-8 study for Bydureon (exenatide) in combination with Forxiga (dapagliflozin)?
• How do experts view SGLT-2/GLP-1 combination therapy as a strategy for diabetics?
• How do KOLs think Bydureon and Forxiga will fare against Jardiance and Victoza?
• Are fixed-dose combination products of a GLP-1 agonist with SGLT-2 inhibitor on the horizon? What are the challenges?
• What are KOLs opinions on the approval of Glyxambi in Europe? 
• How do KOLs view Glyxambi and where is it likely to fit in the treatment strategy?
• Is Glyxambi going to gain market traction; what do KOLs think?
• What do KOLs think of Merck & Co.’s pipeline SDLT2 inhibitor, ertugliflozin?
• Will ertugliflozin based combinations be able to compete and what barriers are they likely to face?